CAMP4 Therapeutics Corp (NASDAQ:CAMP)’s traded shares stood at 50765.0 during the last session. At the close of trading, the stock’s price was $1.43, to imply an increase of 5.93% or $0.08 in intraday trading. The CAMP share’s 52-week high remains $12.30, putting it -760.14% down since that peak but still an impressive 9.09% since price per share fell to its 52-week low of $1.30. The company has a valuation of $28.83M, with an average of 0.19 million shares in intraday trading volume over the past 10 days and average of 319.80K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for CAMP4 Therapeutics Corp (CAMP), translating to a mean rating of 1.00. Of 4 analyst(s) looking at the stock, 1 analyst(s) give CAMP a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy.
CAMP4 Therapeutics Corp (NASDAQ:CAMP) trade information
After registering a 5.93% upside in the last session, CAMP4 Therapeutics Corp (CAMP) has traded red over the past five days. The 5-day price performance for the stock is -4.03%, and -26.29% over 30 days. Short interest in CAMP4 Therapeutics Corp (NASDAQ:CAMP) saw shorts transact 0.49 million shares and set a 3.2 days time to cover.
The extremes give us $5 and $18 for target low and target high price respectively. As such, CAMP has been trading -1158.74% off suggested target high and -249.65% from its likely low.
CAMP Dividends
CAMP4 Therapeutics Corp has its next earnings report out on 2025-May-13. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
CAMP4 Therapeutics Corp (NASDAQ:CAMP)’s Major holders
CAMP4 Therapeutics Corp insiders hold 35.41% of total outstanding shares, with institutional holders owning 56.56% of the shares at 87.57% float percentage. In total, 56.56% institutions holds shares in the company, led by YOUR ADVOCATES LTD., LLP. As of 2024-06-30, the company held over 2.0 shares.
We also have Fidelity Select Portfolios-Biotechnology Portfolio and Victory Portfolios III-Victory Science & Technology Fund as the top two Mutual Funds with the largest holdings of the CAMP4 Therapeutics Corp (CAMP) shares. Going by data provided on Apr 30, 2025, Fidelity Select Portfolios-Biotechnology Portfolio holds roughly 271.89 shares. This is just over 1.35% of the total shares, with a market valuation of $0.39 million. Data from the same date shows that the other fund manager holds a little less at 228.84, or 1.14% of the shares, all valued at about 0.33 million.
